ESWL Versus SOPIL for Treatment of Pancreatic Duct Stones

March 11, 2024 updated by: Jeffrey Easler, Indiana University

Extracorporeal Shock Wave Lithotripsy Versus Single Operator Pancreatoscopy and Intraductal Lithotripsy for the Treatment of Pancreatic Duct Stones

Pancreatic duct stones can cause obstruction of the main pancreatic duct leading to abdominal pain, exocrine pancreatic insufficiency, and recurrent acute pancreatitis. By removing pancreatic duct stones, the obstruction can be relieved, and this can improve symptoms. Small stones can be removed with standard endoscopic retrograde cholangiopancreatography (ERCP) and stone removal, but larger stones may require lithotripsy to break up the stone before removal. The two current methods of lithotripsy include extracorporeal shock wave lithotripsy (ESWL) and single operator pancreatoscopy with intracorporeal lithotripsy (SOPIL).

ESWL is based on concentrating shock wave energy to the stone through an external device. SOPIL is a newer technique based on direct visualization of the stone during ERCP and targeting the stone with a shock wave catheter. There are currently no studies directly comparing ESWL to SOPIL for breaking apart stones in the pancreatic duct, so this study is designed to compare the two techniques.

Objective #1: Obtain pilot data to determine the optimal method of clearing large MPDS Objective #2: Obtain pilot data to assess how effective large MPDS clearance is in improving long term patient centered outcomes Objective #3: Obtain pilot data to measure the cost effectiveness of large MPDS clearance

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Suzette Schmidt, RN
  • Phone Number: 317-278-0691
  • Email: suschmid@iu.edu

Study Contact Backup

Study Locations

    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University Health Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • MPDS located in the head, neck, or neck/body junction of the pancreas
  • MPDS > 5 mm in size
  • Abdominal CT scan, Endoscopic ultrasound, or prior ERCP demonstrating MPDS
  • Abdominal pain related to MPDS
  • Previously failed ERCP performed with intent to clear MPDS, OR MPDS determined by treating physicians to not be amenable to clearance by standard ERCP techniques

Exclusion Criteria:

  • MPDS predominantly located in the body and tail of pancreas
  • Any obstructing MPDS > 5 mm located in the body and tail of pancreas
  • Known pancreatic head stricture precluding passage of the pancreatoscope with endoscopic stone extraction based on prior imaging or prior ERCP
  • Pancreatic head mass
  • Impacted MPDS located at the pancreatic duct orifice
  • Prior attempts at ESWL or SOPIL for MPDS
  • Walled off pancreatic necrosis
  • Active alcohol use, defined as any alcohol use within 2 months
  • Surgically altered anatomy (see text)
  • Gastric outlet obstruction or obstruction precluding passage of the endoscope
  • Standard contraindications to ERCP
  • Implanted cardiac pacemakers or defibrillators
  • Known calcified aneurysms in the path of the shockwave
  • Age < 18 years, pregnancy, incarceration, unwillingness/inability to provide informed consent, or anticipated inability to follow protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ESWL
Extracorporeal shock wave lithotripsy for the treatment of pancreatic duct stones
To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
Active Comparator: SOPIL
Single Operator Pancreatoscopy and intraductal lithotripsy for the treatment of pancreatic duct stones
To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Technical success of complete or partial clearance (≥80% stone clearance) of large main pancreatic duct stone
Time Frame: Up to 24 weeks
This will be described as a proportion of patients with stone clearance. This is defined by the endoscopist's interpretation of the pancreatogram during the time of ERCP and/or subsequent imaging studies. Two blinded endoscopists will review the final pancreatogram to confirm clearance of MPDS
Up to 24 weeks
Mean number of lithotripsy and ERCP procedures needed for clearance of stones or in the attempt to clear stones
Time Frame: Up to 24 weeks
Combined lithotripsy and ERCP procedures
Up to 24 weeks
Procedural related adverse events
Time Frame: Up to 24 weeks
This will be described as a proportion of patients who develop post-procedure pancreatitis, bleeding, infection, perforation, organ injury, symptomatic hematoma, or Steinstrasse resulting in acute stone impaction at the papilla
Up to 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pain scores
Time Frame: through study completion, an average of 1 year
Change in Izbicki pain scores from baseline at 3 months, 6 months, 9 months, and 12 months. The Izbicki pain scale is a validated pain score for chronic pancreatitis using a visual analog scale, frequency of pain, requirement of pain medication, and pain affecting functional ability. The score ranges from 0 to 100 with higher scores suggesting more pain.
through study completion, an average of 1 year
Change in quality of life based on chronic pancreatitis specific instruments: PANQOLI
Time Frame: through study completion, an average of 1 year
Change in the pancreatitis quality of life instrument (PANQOLI) scores from baseline at 3 months, 6 months, 9 months, and 12 months. The PANQOLI score is a validated quality of life score for chronic pancreatitis with specific focus on the domains of physical function, role function, emotional function, and self-worth. The score ranges from 11 to 103, which higher scores suggesting better quality of life.
through study completion, an average of 1 year
Change in narcotic pain medication usage
Time Frame: through study completion, an average of 1 year
Change in daily morphine milligram equivalent usage from baseline at 3 months, 6 months, 9 months, and 12 months
through study completion, an average of 1 year
Change in exocrine insufficiency
Time Frame: through study completion, an average of 1 year
This will be described as a proportion of patients who experience weight gain, resolution of steatorrhea, or no longer require pancreatic enzyme supplementation after stone clearance at 3 months, 6 months, 9 months, and 12 months
through study completion, an average of 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean cost of care for stone clearance
Time Frame: up to 24 weeks
Costs will be estimated by procedural fees including the cost of ESWL, lithotripsy, ERCP, anesthesia, and fluoroscopy.
up to 24 weeks
Health care utilization
Time Frame: through study completion, an average of 1 year
Change in frequency of emergency room visits or hospitalization after treatment
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jeffery J Easler, MD, Indiana University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2019

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

November 6, 2019

First Submitted That Met QC Criteria

November 7, 2019

First Posted (Actual)

November 8, 2019

Study Record Updates

Last Update Posted (Actual)

March 12, 2024

Last Update Submitted That Met QC Criteria

March 11, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pancreatitis

Clinical Trials on ESWL vs SOPIL

3
Subscribe